US PATENT GRANTED FOR ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY; EXCLUSIVITY TO AT LEAST 2039

Melbourne, Australia – 20 May 2024: Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce that a key patent for its lead drug candidate, ATL1102, has been granted in the United States.

Key Points

- The patent, entitled *Uses and Methods for Treating Duchenne Muscular Dystrophy*, is a central component of the company's strategy for protecting market exclusivity for ATL1102 in key territories.

- The patent filing includes key data describing the activity of ATL1102 in this disease, including from the phase IIa study that was recently published in a peer-reviewed scientific journal[1].

- The patent has now been granted by the US Patent and Trademark Office and precludes other companies from commercialising ATL1102 in Duchenne muscular dystrophy in the United States until at least 2039. The patent may thereafter be eligible for a patent term extension of up to five years.

"It is very gratifying to see this patent granted," commented Percheron CEO, Dr James Garner. "The company has put a persuasive body of evidence to patent agencies in key territories, who have reviewed it in detail. The granting of a patent such as this substantially increases the value of ATL1102, and will no doubt be enormously helpful in our future discussions with partners and investors."

Next Steps

Similar applications remain under evaluation by patent authorities in other key territories. The company expects to generally report progress with these via routine disclosures in Appendix 4C filings.

ATL1102 is currently the subject of an ongoing international phase IIb clinical trial in non-ambulant boys with Duchenne muscular dystrophy. Data is expected in 2H CY2024.

~ ENDS ~

[1] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0294847

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.